Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma
- Focus Adverse reactions
- 25 Sep 2017 Planned End Date changed from 1 May 2017 to 1 Apr 2018.
- 18 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 22 May 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2017 as reported by ClinicalTrials.gov record.